Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN) (IMPOCNPIC)

12 de noviembre de 2026 actualizado por: Centre Hospitalier Intercommunal Creteil

Occupational Impact and Chemotherapy-Induced Peripheral Neuropathies (CIPN): A Descriptive Study of Occupational Issues to Guide Occupational Therapy Intervention

Advances in cancer treatment have increased the number of patients living with long-term treatment-related consequences. Among these, chemotherapy-induced peripheral neuropathy (CIPN) is common and can significantly affect patients' quality of life and daily activities. Despite its impact, CIPN remains difficult to manage, and patients often receive insufficient support regarding its functional and occupational consequences.

Occupational therapy remains underutilised in oncology, despite its potential to help patients maintain or regain independence in meaningful daily activities. Collaboration between Advanced Practice Nurses and occupational therapists could improve the identification and management of occupational difficulties associated with CIPN.

The aim of this study is to describe the occupations affected by CIPN using the Canadian Occupational Performance Measure (COPM). The findings will help identify patients' occupational needs and guide future occupational therapy interventions.

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

In 2023, 433,136 new cancer cases were reported in France, accounting for 8.1 million hospital admissions. Thanks to advances in cancer treatment, the number of patients living with long-term consequences of cancer or its treatment is steadily increasing.

Cancer control policies in France have been based on successive Cancer Plans, followed by the adoption of the 2021-2030 Ten-Year Cancer Control Strategy. This strategy is structured around four priority areas, including the second: "Reducing long-term consequences and improving quality of life." Indeed, two out of three people experience lasting effects five years after a cancer diagnosis. This priority aims to promote research to reduce long-term consequences and improve patients' quality of life, as well as to prevent, detect and manage the effects associated with the disease and its treatments. In particular, findings from the VICAN 5 study show that 63.5% of cancer survivors continue to experience disease- or treatment-related consequences five years after diagnosis. Among these patients, 35.3% reported neuropathic pain, which negatively affects their quality of life and daily activities. Chemotherapy-induced peripheral neuropathy (CIPN) is common and remains difficult to manage because of its limited response to pharmacological treatments.

Current literature highlights a lack of support and care for patients experiencing CIPN, as well as insufficient knowledge regarding its impact on their daily activities and occupations.

The cancer care pathway can be divided into three main stages: diagnosis disclosure, treatment, and post-cancer care. Advanced Practice Nurses (APNs) can intervene at different stages of this pathway. They play a major role in long-term follow-up, particularly in identifying and monitoring treatment-related side effects and long-term consequences. However, their role, which primarily focuses on screening and monitoring, does not allow them to provide specific interventions aimed at improving the management of CIPN-related difficulties.

Occupational therapy aims to help individuals regain or maintain their independence in carrying out everyday activities. It offers a wide range of interventions but remains underutilised in oncology, for several reasons, including limited awareness of the profession, insufficient knowledge of its potential benefits, and difficulties accessing occupational therapy services.

In the management of CIPN, collaboration between Advanced Practice Nurses and occupational therapists could help establish effective care pathways, combine their respective expertise and promote patients' engagement in activities affected by CIPN.

The objective of this study is to describe the occupations (activities or groups of activities performed regularly and considered meaningful and valuable by individuals) affected by CIPN, using the Canadian Occupational Performance Measure (COPM).

Occupational performance is defined as an individual's ability to perform meaningful occupations adequately, efficiently and to their own satisfaction.

Tipo de estudio

De observación

Inscripción (Estimado)

50

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Créteil, Francia, 94000
        • Reclutamiento
        • Centre Hospitalier Intercommunal de Créteil
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

Adult patients with chemotherapy-induced peripheral neuropathy, grade 2 or 3 according to CTCAE: caused by paclitaxel in cases of breast cancer or by oxaliplatin in cases of colorectal cancer.

Patients must be able to carry on a conversation in French.

Descripción

Inclusion Criteria:

  • Patient treated for breast cancer or colorectal cancer, who has not previously received paclitaxel or oxaliplatin.
  • Patient with grade 2 or 3 peripheral neuropathy, according to the CTCAE criteria, occurring during their treatment.
  • Patient able to communicate in French.
  • Patient aged 18 years or older

Exclusion Criteria:

  • History of neuropathy prior to treatment.
  • Refusal to participate in the study.
  • Protected persons (pregnant or breastfeeding women, individuals under guardianship or curatorship, minors, individuals deprived of their liberty, or individuals unable to provide informed consent).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_ONLY
  • Perspectivas temporales: PROSPECTIVE

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Description of the occupational issues identified as priorities by patients
Periodo de tiempo: 3 months

Describe the occupational issues identified as priorities by patients based on the categories and subcategories of occupations defined by the MCRO

3 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Patient verbatim
Periodo de tiempo: 3 months

Patient verbatim statements regarding their priority occupational issues, grouped according to the MCRO categories and subcategories

3 months
Performance and satisfaction scores
Periodo de tiempo: 3 months

Performance and satisfaction scores obtained across each category and subcategory of the MCRO

3 months
Number and percentages of priority problematic occupations
Periodo de tiempo: 3 months

Number and percentages of priority problematic occupations, coded according to the categories and subcategories of the MCRO, based on the two types of treatment received.

3 months
Number and percentages of priority adverse events
Periodo de tiempo: 3 months

Number and percentages of priority adverse events, coded according to the categories and subcategories of the MCRO, based on the two CTCAE grading scales

3 months
Average time to onset of NPICs by treatment received
Periodo de tiempo: 3 months

Average time to onset of NPICs by treatment received. The time to onset of NPICs is defined as the interval (in days) between the start date of treatment and the date of NPIC diagnosis

3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

9 de noviembre de 2026

Finalización primaria (Estimado)

9 de febrero de 2027

Finalización del estudio (Estimado)

9 de febrero de 2027

Fechas de registro del estudio

Enviado por primera vez

12 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

19 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir